InMed Pharmaceuticals (INM) Gross Margin: 2022-2025
Historic Gross Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to 35.99%.
- InMed Pharmaceuticals' Gross Margin fell 302.00% to 35.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.69%, marking a year-over-year increase of 197.00%. This contributed to the annual value of 34.53% for FY2025, which is 1058.00% up from last year.
- According to the latest figures from Q3 2025, InMed Pharmaceuticals' Gross Margin is 35.99%, which was down 18.57% from 44.20% recorded in Q2 2025.
- InMed Pharmaceuticals' 5-year Gross Margin high stood at 67.95% for Q2 2023, and its period low was -153.07% during Q3 2022.
- Its 3-year average for Gross Margin is 31.88%, with a median of 35.99% in 2025.
- Over the last 5 years, InMed Pharmaceuticals' Gross Margin had its largest YoY gain of 15,542bps in 2023, and its largest YoY loss of 4,026bps in 2023.
- InMed Pharmaceuticals' Gross Margin (Quarterly) stood at 27.92% in 2022, then tumbled by 178bps to 26.14% in 2023, then soared by 1,532bps to 41.46% in 2024, then slumped by 302bps to 35.99% in 2025.
- Its last three reported values are 35.99% in Q3 2025, 44.20% for Q2 2025, and 13.92% during Q1 2025.